Brokerages Set The Chemours Company (NYSE:CC) Target Price at $17.56

The Chemours Company (NYSE:CC - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine ratings firms that are covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $17.22.

A number of research firms recently weighed in on CC. Mizuho set a $15.00 price target on Chemours in a research note on Tuesday, April 15th. UBS Group cut their target price on shares of Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Wall Street Zen lowered shares of Chemours from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. Barclays decreased their price objective on Chemours from $16.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday. Finally, BMO Capital Markets reduced their target price on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a research report on Wednesday, February 19th.

Chemours Stock Performance

Chemours stock traded up $0.04 on Wednesday, hitting $10.15. The company's stock had a trading volume of 5,382,386 shares, compared to its average volume of 2,143,667. The company has a fifty day moving average price of $11.55 and a 200-day moving average price of $15.63. The firm has a market cap of $1.52 billion, a P/E ratio of 17.81 and a beta of 1.76. Chemours has a one year low of $9.33 and a one year high of $25.80. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.06). The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.36 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. The company's revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.32 EPS. On average, equities analysts anticipate that Chemours will post 2.03 earnings per share for the current year.

Chemours Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Monday, June 16th. Stockholders of record on Monday, May 19th will be paid a $0.0875 dividend. This represents a dividend yield of 3.17%. The ex-dividend date is Friday, May 16th. Chemours's dividend payout ratio (DPR) is 175.00%.

Insiders Place Their Bets

In other Chemours news, CFO Shane Hostetter purchased 4,450 shares of the stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average price of $11.28 per share, with a total value of $50,196.00. Following the acquisition, the chief financial officer now owns 59,694 shares in the company, valued at approximately $673,348.32. The trade was a 8.06% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.34% of the stock is currently owned by corporate insiders.

Institutional Trading of Chemours

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Chemours by 8.3% in the first quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company's stock worth $223,069,000 after purchasing an additional 1,263,047 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Chemours by 23.8% during the 4th quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company's stock valued at $73,907,000 after purchasing an additional 839,849 shares in the last quarter. Millennium Management LLC raised its stake in Chemours by 60.4% in the 1st quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company's stock worth $54,428,000 after acquiring an additional 1,515,520 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Chemours by 17.5% in the 1st quarter. American Century Companies Inc. now owns 1,909,149 shares of the specialty chemicals company's stock valued at $25,831,000 after acquiring an additional 284,130 shares during the last quarter. Finally, Norges Bank acquired a new stake in Chemours during the fourth quarter worth about $30,702,000. Hedge funds and other institutional investors own 76.26% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.